Pioneering a non-glucose-based dialysis solution designed to make treatment safer, longer-lasting, and more personalized.
scroll downAt Opterion, our mission is to relentlessly innovate for those living with chronic kidney disease, creating breakthrough therapies that put patients first — because every person deserves a future free from the burdens of outdated treatments.
Kidney disease affects millions of people worldwide, with many patients ultimately requiring dialysis.
Living with kidney disease worldwide—and growing ~8% per year.
Ranking among the top mortality drivers worldwide and still rising.
Fueled globally by the rising rates of diabetes, hypertension, and obesity.
Consuming a massive portion of the healthcare budget to treat less than 1% of the population.
The burden of disease has grown, but treatment technology has lagged for decades.
For people living with chronic kidney disease, treatment options are limited and life-altering. Improving Peritoneal Dialysis (PD) represents a compelling opportunity to enhance patients' lives while enabling a scalable, cost-effective model for healthcare systems.
Most patients rely on in-center hemodialysis, which is time-consuming, physically demanding, and highly disruptive to daily life. While Peritoneal Dialysis (PD) offers a gentler, at-home alternative linked to better early outcomes, it has seen little innovation in decades. Today's PD is constrained by outdated, glucose-based solutions that cause metabolic stress and limit long-term use.
Understand kidney care
OPT101 is a novel, non-glucose-based osmotic agent designed to address the significant limitations of current PD therapies – improving outcomes and quality of life for patients with advanced chronic kidney disease (CKD).
Delivers rapid and sustained ultrafiltration across both day and night dwells.
Designed to minimize glucose spikes and metabolic distress.
Designing multiple concentrations to allow for highly personalized therapy.
A gentler alternative that actively preserves the patient's residual kidney function.
Designed to prevent the peritoneal damage caused by glucose, extending the window for PD treatment.
Empowers patients to safely manage their treatment at home, at work, or while traveling.
We are always looking for dedicated and curious individuals who want to contribute to our mission of advancing breakthrough therapies for patients with chronic kidney disease. Join us and be part of our pioneering spirit.
View Open Roles
Stay up to date with our most recent announcements and development milestones.
